ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) (NASDAQ:IBRX)

Market and analyst sentiment on ImmunityBio, Inc. ( IBRX ) has waxed and waned since I have been watching the company starting back in late 2023 , prior to the approvalI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analyst’s Disclosure: ...